Antibody-Drug Conjugate Market Poised for Significant Growth Through 2031

The global market for Antibody-Drug Conjugates (ADCs) is set for significant expansion from 2026 to 2031, with projections estimating its valuation to reach between $22 billion and $32 billion USD. During this period, the market is anticipated to grow at a compound annual growth rate (CAGR) ranging from 15% to 25%.

ADCs are a class of biopharmaceutical drugs designed as targeted therapies for cancer treatment. They function as "biological missiles," engineered to deliver potent cytotoxic agents directly to tumor cells while sparing healthy tissues, thereby reducing the systemic toxicity associated with traditional chemotherapy.

Structurally, an ADC consists of three main components: a monoclonal antibody, a cytotoxic payload, and a chemical linker that attaches the payload to the antibody. The antibody component targets and binds to specific antigens on cancer cells, leading to internalization. Once inside the cell, the linker is cleaved, releasing the potent cytotoxic agent to induce cell death.

The market's rapid growth is driven by an increase in FDA approvals, technological advancements in linker and payload stability, and an expanding scope of addressable indications. The commercial success of therapies targeting HER2 and TROP2, alongside the transition of ADCs into earlier treatment lines and combination therapies, are key factors supporting this anticipated market surge.